retatrutide clinical trial information A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide - Wikipedia

GLP-3RT is a multi receptor research peptide studied in controlled laboratory environments for its interaction with GLP-1, GIP, and glucagon receptor signaling pathways

20mg vial add 5.0mL (4mg/mL)

It does not activate GIPR

The difference is a systematic vetting process that separates researchers who get legitimate, research-grade retatrutide from those who fund a scam operation and learn an expensive lesson about cutting corners on due diligence

Retatrutide vs Tirzepatide (Mounjaro): 28.7% vs 22.5% (2026 Data) Phase 3 trial comparison: Retatrutide 28.7% weight loss vs Tirzepatide 22.5%

Studies concerning indirect mechanisms linking GLP-1 RAs, to coronary events are not included